Billionaire Mark Cuban harnesses OpenAI's Sora platform to generate AI videos of himself promoting his pharmaceutical company Cost Plus Drugs, with the viral clips featuring him delivering promotional messages and dancing garnering tens of thousands of views as a cost-free marketing experiment.
Google enhances its Jules AI coding assistant with new command line tools and API support, while Nvidia introduces a revolutionary 4-bit training format that cuts AI training costs, and MIT researchers use generative AI to dramatically accelerate antibiotic discovery from years to much shorter timeframes.
AstraZeneca strikes a massive $555 million partnership with Algen Biotechnologies, combining cutting-edge AI platform 'AlgenBrain' with CRISPR gene technology to revolutionize drug discovery for chronic inflammatory diseases and unlock next-generation immunology therapies.
AI agents powered by large language models now assist scientists with research tasks like data curation and literature reviews, while new collaborative systems mimic medical teams to analyze drug trials and identify unexpected therapeutic effects, though current technology still requires human oversight due to reliability limitations.
MIT and McMaster University researchers use AI to discover enterololin, a revolutionary narrow-spectrum antibiotic that targets harmful gut bacteria causing Crohn's disease while preserving beneficial microbes, showing promising results in mouse studies and advancing toward human trials.
RNA structure prediction remains far behind protein prediction as AlphaFold3 struggles with RNA's extreme flexibility, with only 7,759 RNA structures mapped versus 216,212 proteins, though most RNA therapeutics like mRNA vaccines rely on secondary structure which scientists can now predict with high accuracy.
Eli Lilly unveils TuneLab, an AI-driven drug discovery platform backed by a $1 billion research investment, offering biotech companies access to AI models built on Lilly's extensive drug data and joining Lilly Catalyze360's offerings for biotech partners.
MIT researchers unveil VaxSeer, an AI tool that accurately predicts dominant flu strains and optimizes vaccine design months ahead, outperforming WHO selections in a 10-year study by simulating virus evolution and vaccine responses using deep learning models.
Researchers harness AI to uncover abaucin, a groundbreaking antibiotic disrupting lipoprotein trafficking, offering a potent weapon against drug-resistant Acinetobacter baumannii bacteria, sparking hope for treating stubborn wound infections.
Generative AI pioneers novel antibiotics that disrupt bacterial cell membranes, offering potential solutions against drug-resistant gonorrhea, MRSA, and other superbugs in the ongoing battle against antimicrobial resistance.